Subtype
Hepatocellular Carcinoma
CI-CAN-00002853HCC · LIHCExplore in graph →
693 active trials13 approved drugs9 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002853HCC · LIHCExplore in graph →
Clinical trials
3,123 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (356)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05683548 | Replicor Compassionate Access Program(RCAP) | no longer available | — | — | Replicor Inc.INDUSTRY | 5 | Feb 17, 2025 | clinicaltrials |
| NCT02960620 | Therasphere for Unresectable Primary or Secondary Liver Neoplasia | no longer available | — | — | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 28, 2022 |
| NCT00701168 | Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer | no longer available | — | — | Leo W. Jenkins Cancer CenterOTHER | 1 | Aug 23, 2017 | clinicaltrials |
| NCT02082691 | Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma | no longer available | — | — | Devalingam MahalingamOTHER | 0 | Mar 10, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Feb 17, 2025source: clinicaltrials